Dyskeratosis congenita (DC) is characterized by reticular skin pigmentation, oral leukoplakia and abnormal nails. Patients with DC have very short telomeres and approximately one-half have mutations in telomere biology genes. A majority of patients with DC develop BM failure (BMF). Hematopoietic cell transplantation (HCT) represents the only known cure for BMF in DC, but poses significant toxicities. We report six patients who underwent allogeneic HCT with a novel nonmyeloablative conditioning regimen specifically designed for DC patients. Graft sources included related PBSCs (1), unrelated BM (2) and unrelated double umbilical cord blood (3). Complete donor engraftment was achieved in five of six patients. One patient had initial autologous hematopoietic recovery, which was followed by a second transplant that resulted in 88% donor chimerism. With a median follow-up of 26.5 months, four patients are alive, three of whom were recipients of unrelated grafts. We conclude with this small study that encouraging short-term survival can be achieved with HCT in patients with DC using a preparative regimen designed to promote donor engraftment and minimize life-threatening disease-specific complications such as pulmonary fibrosis. Long-term follow-up will be crucial with respect to individualized patient care with each of the transplanted individuals.
Introduction
Dyskeratosis congenita (DC) is characterized by the clinical triad of reticular skin pigmentation, oral leukoplakia and abnormal nails. Patients with DC have abnormally short telomeres and approximately one-half have mutations in genes important in telomere biology genes. The clinical complications of DC are broad and include BM failure (BMF), cancer, pulmonary fibrosis, liver abnormalities and esophageal stenosis. [1] [2] [3] Telomeres consist of nucleotide repeats, (5 0 -TTAGGG-3 0 ) n , and a protein complex at chromosome ends. Telomeres are critical for the maintenance of chromosome stability. 4 Mutations that result in DC occur in genes that directly interact with telomerase, the reverse transcriptase that adds nucleotide repeats to chromosome ends, (DKC1, TERC, TERT, NOP10 and NHP2), or with one component of the shelterin telomere protein protection complex (TINF2). 5 The most severely affected patients often have the diagnostic triad, very short telomeres (less than first percentile for age), BMF and other complications. Other, less severely affected patients may still have very short telomeres, but fewer clinical findings.
Hematopoietic cell transplantation (HCT) is a life-saving measure for patients with malignant and non-malignant diseases. However, the fully myeloablative and immunosuppressive regimens typically a prerequisite for donor cell engraftment are commonly associated with significant tissue injury. This systemic toxicity is frequently extreme in patients with inherited defects in genome maintenance, which cause several BMF syndromes, including DC and Fanconi anemia (FA), and for whom HCT is at present the only definitive BMF therapy. [6] [7] [8] [9] This patient population is also at higher risk of developing MDS and AML. 10, 11 In addition, previous studies have estimated that BMF and its associated immunodeficiency are responsible for 60-70% of premature mortality in DC patients. 9 Past efforts to correct BMF in DC by allogeneic HCT have resulted in unacceptable transplant-related mortality, especially from pulmonary, vascular and hepatic complications.
7,9,12-14 Therefore, we hypothesized that a nonmyeloablative conditioning regimen designed with regard to the clinical complications of DC may result in better outcomes. We designed a prospective DC-specific nonmyeloablative transplantation regimen to determine whether engraftment can be achieved with less toxicity. Our approach used fludarabine, cyclophosphamide, low dose TBI and alemtuzumab. The rationale behind these choices is expanded in the discussion. In this study, we report successful shortterm outcomes, including the ability to achieve favorable results with unrelated donor sources of hematopoietic stem cells, which has been an even greater challenge for these patients in the past. 7, 9, 12 Patients and methods Six patients underwent allogeneic HCT with nonmyeloablative conditioning specifically designed for DC patients. This transplant protocol was approved by the Institutional Review Board at the University of Minnesota and the University of Colorado at Denver. Informed consent was obtained from the subjects or their guardians before HCT. The clinical trial has been registered on www. The classification of a patient with DC has evolved since the advent of clinical telomere length testing and genetic testing. Initially, the diagnosis was based only on the presence of the classic clinical triad. The diagnosis of DC was suspected clinically in five of our six patients (ages 2, 5, 18, 24 and 29) with BMF by the presence of at least two features of the classic triad or a feature of the triad plus another condition also observed in patients with DC. The diagnosis was then supported by documentation of very short telomeres with automated multicolor flow cytometry FISH (flow FISH) of leukocyte subsets (less than first percentile of normal for age). 15 Research and clinical gene sequencing was also performed as described. 5 A 6th patient (age 25) was classified as 'DC-like' 3 as a result of BMF with very short telomeres but no features of the DC diagnostic triad or other physical findings and no identifiable mutation in a known DC gene.
The nonmyeloablative regimen included a single dose of cyclophosphamide (50 mg/kg) intravenously (i.v.) on day -6, fludarabine (40 mg/m 2 ) i.v. once daily for 5 consecutive days from day À6 to day À2, alemtuzumab (0.2 mg/kg) i.v. once daily for 5 consecutive days from day À10 to day À6 and a single 200 cGy dose of TBI on day À1. The lowdose TBI was delivered side-to-side, instead of anteriorposterior, with the patient in a seated position and the arms resting at the side of the thoracic cage. This enabled the arm to provide a natural pulmonary compensation with respect to the delivered radiation. There was no other shielding provided. In the case of patient 1, after the inability to achieve cord blood donor-derived hematopoiesis with the initial transplant, a second cord blood was infused after a preparative regimen consisting of a 5-day course of ATG, supplemented by a 28-day course of prednisone.
GVHD and graft failure prophylaxis consisted of cyclosporine and mycophenolate mofetil. Cyclosporine was started on day À3 and adjusted to maintain a level of 4200 mg/L (initial dose 2.5 mg/kg every 12 h for patients weighing 40 kg or more, or 2.5 mg/kg every 8 h for patients weighing under 40 kg) until day þ 180 with a subsequent taper over 10 weeks unless GVHD was present. Mycophenolate mofetil was started on day 0 using a dose of 15 mg/kg (maximum 1 g) three times a day until day þ 30, at which time it was stopped unless GVHD was present.
Stem cell sources included one HLA-matched related PBSC graft (6/6 HLA match, patient 2), two from unrelated donor BM grafts (one 7/8 HLA match, one 8/8 HLA match, patients 3 and 4, respectively) and three from double umbilical cord blood grafts (one set of 4/6 and 4/6 HLA match, two sets of 4/6 and 5/6 HLA match, patients, 1, 5 and 6, respectively). HLA typing of the patient and donor was performed at the allele level for HLA-A, B, C and DRB1 in the case of marrow or PBSCs. In the case of umbilical cord blood, HLA typing was performed at Ag level for HLA-A and B and allele level for DRB1. All grafts were unmanipulated. Hematopoietic chimerism was assessed on peripheral blood leukocyte DNA by competitive PCR analysis of variable tandem repeat regions. 16 The Kaplan-Meier product limit estimator was used to calculate actuarial survival probabilities and cumulative incidences in cases reported from the literature in the absence of competing risks. Subjects were censored at death. Subgroup outcomes were compared using the logrank rest for equality of survivor functions.
17 Stata10 (StatCorp LP, College Station, TX, USA) was used for these analyses. A P-value of p0.05 was considered to be significant.
Results
The clinical characteristics and pre-transplant evaluations are shown in Table 1 . Two of six patients had no evidence of the characteristic clinical mucocutaneous triad at the time of presentation with BMF, although one of those patients fit criteria for Hoyeraal-Hreiderasson syndrome, a severe form of DC. Only two of six patients had an identifiable genetic mutation associated with DC (patient 1 had a mutation in DKC1 and patient 2 had a mutation in TINF2), but all six had very short leukocyte subset telomere length measurements by flow FISH. All patients had progressive pancytopenia with evidence of marrow hypocellularity on biopsy, but normal cytogenetic analysis on BM aspirates. No patients had evidence of myelodysplasia or leukemic transformation.
Graft characteristics and transplant outcomes are provided in Table 2 . Complete donor engraftment after the initial stem cell infusion was achieved in five of six patients, with patient 1 showing autologous hematopoietic recovery. After a second transplant, 88% donor chimerism was achieved in this patient. This was documented on a BM aspiration performed on day þ 20 after the second transplant.
Four patients are alive (67%) with a median follow-up of Other significant transplant-related morbidity included grade II acute skin GVHD (patient 4), grade IV acute gastrointestinal GVHD (patient 5), and limited chronic skin GVHD (patient 2), all of which were successfully treated with systemic and topical steroids. Patient 2 also had CMV reactivation at low levels that was treated successfully with i.v. ganciclovir followed by oral valganciclovir. Patient 6 had skin manifestations of Varicella Zoster virus, which was successfully treated with i.v. and oral acyclovir.
To better understand the HCT outcomes in this study and the literature, we also reviewed the literature on HCT in DC. There have been some promising results using reduced-intensity conditioning or nonmyeloablative preparations in DC. Various regimens have been examined, but there is not yet a commonly accepted standard. 9, 12, 14, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Table 3 summarizes the reported experience of HCT for patients with DC using reducedintensity conditioning, including specifics of donors, regimens and outcomes. Kaplan-Meier analysis revealed that overall cumulative survival was 65%, with related donor recipients having better survival compared with unrelated donor transplants (91 vs 30%, respectively, P ¼ 0.05). However, the follow-up intervals for the two donor types are short and not very different from other historical data. 10 
Discussion
This study was designed to assess clinical complications and outcomes of a nonmyeloablative regimen that included agents known to promote donor engraftment in other /L, rst of 7 days. c In spite of not meeting the criteria for myeloid recovery, a BM biopsy on day +20 was used to evaluate chimerism.
BMF disorders (for example, fludarabine) and excluded agents (for example, BU and high-dose TBI) that can lead to life-threatening disease-specific extra-medullary side effects, such as pulmonary fibrosis. Preliminary data suggest that this strategy may result in improved shortterm outcomes in patients with DC. Ongoing follow-up is required to assess the long-term success of this nonmyeloablative regimen in DC.
Historical results with myeloablative conditioning resulted in death in 14 of 21 patients with DC; there were no survivors who received unrelated sources of stem cells. 2, 9, 22 In a review of 65 cases of allogeneic HCT for DC with all intensity types, matched related donor transplants fared better, but long-term outcome was poor with late pulmonary complications. 10 The OS was 24% at 11 years after HCT. The matched related donor group had 71% cumulative survival at over 5 years, while the alternative donor group had a cumulative survival of 31% at 2 years. The longest survivor in the matched related donor group died at 20 years after HCT from pulmonary fibrosis, and the longest survivor in the unrelated group died from pulmonary fibrosis at 10 years. 10 There are four important elements to the design of our nonmyeloablative strategy: (1) incorporation of fludarabine, (2) reduction in cyclophosphamide dose, (3) the use of low-dose TBI and (4) the use of alemtuzumab instead of ATG. Patients with DC are at high risk of pulmonary fibrosis and liver dysfunction because of their disease. Thus, we specifically dose-reduced or excluded agents known to be associated with severe organ-specific toxicity.
The use of fludarabine in HCT preparative regimens has been important in the reduction of intensity in several settings. This strongly immunosuppressive, less myeloablative agent has been used successfully in reduced-intensity conditioning for a variety of settings including acquired severe aplastic anemia, 30 other BMF syndromes such as FA, 8 and previously in DC. [19] [20] [21] [22] 25, 26 Fludarabine is generally well tolerated with limited extra-medullary toxicity. Conventional HCT agents that may have severe organspecific toxicity, especially pulmonary and hepatic complications, include BU 31, 32 and melphalan. 33, 34 The exclusion of these medications from the preparative regimen is highly desirable based on the previous experience with them for DC patients. Although the use of cyclophosphamide at higher doses may result in significant morbidity and potentially mortality, reduction in the total dose by inclusion of agents like fludarabine has resulted in reduction in toxicity and better survival. 21, 22, 26 Use of TBI in DC patients is also considered undesirable because of its toxicity profile, including potential pulmonary, hepatic and dermatologic complications. 9, 35 This is described primarily with full-dose TBI, as opposed to the low-dose TBI used in this protocol, which has previously been successful in DC patients. 21, 25 The additional consideration of patient positioning to achieve partial pulmonary compensational shielding is an important aspect to the continued inclusion of low-dose TBI in the reducedintensity conditioning regimen. Although the elimination of TBI may result in decreased toxicity and late complications, this may increase the risk for graft failure. This has been shown in patients with FA in the matched unrelated donor setting when low-dose TBI is removed. 6 The incorporation of alemtuzumab, a humanized MoAb directed at CD52, was chosen as a method of achieving in vivo T-cell depletion. It is more immunosuppressive than alternatives, including ATG, as it targets T cells, B cells, monocytes and macrophages. 36 Recipient or in vivo T-cell depletion has been shown to be important in reducing the risk of GVHD in other BMF settings such as FA. 8 As with fludarabine, immunosuppression with alemtuzumab has the potential to provide for de-escalation of regimen intensity while still achieving donor-derived engraftment. In addition, the use of alemtuzumab in transplantation has previously been shown to reduce GVHD more effectively than ATG, 37 and may reduce the risk of post transplant lymphoproliferative disorder compared with ATG. 38 The major concern with the use of alemtuzumab is infectious complications, 37 including viral pathogens such as adenovirus, 39 which proved fatal in one of our patients. New approaches using alemtuzumab in combination with a second MoAb directed at CD45 have also shown promise. Two DC patients were treated with this combination in a different study, one with a matched unrelated donor who died and one with a matched related donor who is still alive. 18 Our data show encouraging OS of four of six patients (67%), including three of five patients (60%) from unrelated donor sources, a source that has been difficult in the past. 9, 10, 12, 14, 18, 28 In addition, of particular note with our nonmyeloablative regimen has been the absence of pulmonary or liver complications during and immediately after HCT. The mortality associated with this regimen was limited to infectious etiologies. One episode of adenovirus sepsis occurred within the first 3 months post transplant occurred in the patient with HoyeraalHreiderasson syndrome, who came to HCT with multiple co-morbid conditions. The second infection-related death was due to uncharacterized sepsis in a neutropenic patient who left the hospital against medical advice. Survivor follow-up remains relatively short (between 12 and 45 months), and thus long-term complications cannot yet be discussed.
It also remains to be observed whether resolution of BMF substantially alters the natural history of the disease. 9 The risk of cancer has been reported to be 10-fold greater than in the general population with a cumulative incidence up to 50% by age 50 in the DC population. 10 These are primarily skin, head and neck, and anogenital cancers, 10 resembling what is observed in patients with FA. 40, 41 Cancer and pulmonary disease follow BMF as the causes of premature mortality for DC patients. 9, 10 It is important to identify these patients early in life in order to screen for BMF, MDS, AML and solid tumors. It is possible that early diagnosis could lead to improved outcomes. It is also important to screen patients that present with aplastic anemia for DC because some patients can present with BMF alone, as occurred with one of our patients.
Patients with DC require modification of their HCT conditioning because of the increased risks associated with full myeloablative preparative regimens. In such instances, we would recommend a disease-specific protocol using nonmyeloablative conditioning to help avoid the potential hepatic and pulmonary complications. Carrier detection in family members is important for both genetic counseling and the donor selection process for HCT as treatment for BMF. If a pre-symptomatic individual with DC was used as the donor source, there would be a high risk for failure of engraftment. 15, 42, 43 As the underlying genetic defect cannot yet be corrected in non-hematopoietic lineages, patients with DC should continue to be followed by a comprehensive, multidisciplinary team in the post transplant period. Follow-up should include regular skin, oral, pulmonary and genitourinary exams. 3, 7 Concurrent with a better understanding of treatment and surveillance there is an ongoing need for continued research into the underlying etiologies, molecular biology and genetics of telomere shortening to address the basic nature of this disease.
